xBiologix designs, builds, customizes & validates biomarker profiling products & protocols for solid tissue imaging using our patent pending, click-chemistry reagents & conventional multiplexed immunofluorescent platforms. Our multispectral imaging, antibody-oligo products characterize tumor microenvironments & surrounding tissue with a single incubation of (4-20) primary antibodies & gentle signal removal/re-imaging protocol. This simplified, “one pot” staining protocol is uniquely suited to conventional autostaining & multispectral imaging platforms, & amenable to workflow standardization & validation supporting research & clinical laboratory processes. | xBiologix provides multiplexed, fluorescent microscopy products and service supporting our spatial biology customers. Our ready-to-use, platform independent, pre-validated, massively multiplexed immunofluorescent IHCs (mIHC/IF) protocol radically simplifying the published cyclic protocols— a.k.a cycIF. We seek to partner with small oncology focused drug developers who want to reliably identify potential trial participants by screening patient resected tumors for the candidate’s mode of action.
WIENER LAB.
We develop, manufacture and market integrated solutions that enable IVD diagnostics in more than 50 countries around the world. We offer a broad line of products for clinical laboratories and blood banks that enable accurate and timely diagnoses. We generate key and relevant information for medical decision making, understanding the laboratory as a crucial link in the health chain. | We develop, manufacture and market integrated solutions that enable IVD diagnostics in more than 50 countries around the world. We offer a broad line of products for clinical laboratories and blood banks that enable accurate and timely diagnoses. We generate key and relevant information for medical decision making, understanding the laboratory as a very important player in the health system. | Wiener lab. is an innovation-driven multinational from Argentina, with over six decades of experience in the in vitro diagnostics (IVD) industry. With a presence in more than 50 countries, the company continues to grow across Latin America, South Asia, and Europe. Its mission is to deliver smart, reliable, and accessible diagnostic solutions for healthcare systems worldwide. At the heart of its innovation engine is the Centre for Research and Biotechnology (CIBio), where a diverse team of scientists and engineers leads the development of new technologies. The company promotes open innovation by fostering strategic partnerships with academic institutions, regulatory bodies, and clinical collaborators. Wiener lab. actively seeks global partners for OEM manufacturing, technology transfer, and co-development projects. These collaborations are essential for enhancing technological capabilities and providing quicker, more adaptable solutions to meet evolving healthcare demands. The product portfolio includes clinical chemistry, molecular biology, hematology, hemostasis, immunology, urinalysis, chemiluminescence, and ESR, all developed in certified manufacturing facilities that comply with ISO and FDA requirements.
VivoSphere LLC
At VivoSphere, we address a critical industry challenge: the early-stage identification of ineffective or toxic drug candidates to prevent costly failures in clinical trials. With VivoSphere technology, we create more human-like tissue models for more human-like drug responses. By offering three-dimensional tissue-engineered models that mimic human physiological responses more closely than traditional two-dimensional cell cultures, VivoSphere empowers pharmaceutical companies to improve the safety and efficacy of therapeutics, reduce reliance on animal testing, and make more informed decisions faster while reducing costs.
Veeda Lifesciences
For nearly two decades, Veeda Lifesciences has been a trusted partner in drug development, supporting pharmaceutical, biotech, and specialty healthcare companies in bringing innovative therapies to patients worldwide. Our global presence spans across 9 countries and 26 geographies, allowing us to offer localized expertise while maintaining a broad international reach. By combining scientific excellence, regulatory expertise, and cutting-edge technology, we ensure the execution of efficient, high-quality clinical trials that accelerate the drug development process. A Strategic Partner in Drug Development Veeda Lifesciences partners with innovator companies to navigate the intricate landscape of clinical research and drug development. Our comprehensive suite of services covers: Strategic Consulting: We provide expert guidance in trial design, regulatory pathways, and market access strategies, ensuring seamless progression from preclinical to clinical phases. Regulatory Support: Our regulatory affairs team assists with dossier preparation, regulatory submissions, and interactions with health authorities, streamlining the approval process. Operational Excellence: We offer end-to-end trial management solutions, including site selection, patient recruitment, monitoring, data management, and biostatistical analysis. Expertise Across Multiple Therapeutic Areas With deep domain expertise in key therapeutic areas, Veeda has played a pivotal role in advancing clinical research in: Oncology & Hematology: Our contributions include supporting one of the largest global multiple myeloma trials across 24 countries. By leveraging AI-driven patient recruitment strategies and real-world data, we optimize site selection and accelerate trial timelines. Dermatology: We have successfully executed clinical trials for novel dermatological therapies, addressing conditions such as psoriasis, atopic dermatitis, and skin cancers. Endocrinology & Metabolic Disorders: Veeda has been instrumental in conducting trials for diabetes, obesity, and other endocrine disorders, ensuring the safety and efficacy of new treatment modalities. Other Specialties: Our expertise extends to cardiovascular diseases, infectious diseases, autoimmune disorders, and rare diseases, enabling comprehensive clinical research solutions across various indications. Comprehensive Clinical Development Lifecycle Support Veeda Lifesciences offers integrated solutions across the entire clinical development lifecycle, ensuring scientific rigor, regulatory compliance, and operational efficiency at every stage: Early-Phase Studies: First-in-Human (FIH) and Phase I trials Bioavailability & bioequivalence (BA/BE) studies Pharmacokinetics (PK) and pharmacodynamics (PD) evaluations Adaptive trial designs to optimize early-stage decision-making Late-Stage Clinical Trials: Phase II-IV multi-regional clinical trials (MRCTs) Patient-centric study designs incorporating decentralized trial models Site feasibility assessments and accelerated patient enrollment strategies Global regulatory submissions and post-marketing surveillance Advanced Capabilities and Technology-Driven Approach Our commitment to technological innovation enhances trial efficiency and data integrity through: Bioanalytical Research & Central Lab Services: High-quality analytical testing for small molecules, biologics, and biosimilars, ensuring accurate pharmacokinetic and immunogenicity assessments. Digital Trial Management: AI-powered platforms for real-time data capture, electronic trial management, and remote monitoring, optimizing trial workflows. Patient Engagement Solutions: Digital tools to enhance patient retention, adherence, and real-world evidence generation, improving trial outcomes. Pharmacovigilance & Safety Monitoring: Comprehensive adverse event reporting and risk mitigation strategies, ensuring regulatory compliance and patient safety. Biopharmaceutical Development Expertise Veeda Lifesciences offers a comprehensive suite of services tailored to support the development of biopharmaceuticals, including biologics and biosimilars. Our expertise encompasses non-clinical testing solutions designed to ensure safety, efficacy, and regulatory compliance for complex biological therapies. Key Biopharma Services: Preclinical Research: We conduct rigorous preclinical studies to assess the safety and biological activity of biotherapeutic candidates, providing a solid foundation for clinical development. Bioanalytical Support: Our bioanalytical services include method development, validation, and high-throughput sample analysis, delivering precise data essential for regulatory submissions. Regulatory Consulting: We offer strategic guidance on regulatory pathways for biologics and biosimilars, assisting with dossier preparation and interactions with health authorities to streamline approvals. By integrating these services, Veeda Lifesciences ensures a seamless transition from discovery to market for biopharmaceutical products, upholding the highest standards of scientific integrity and patient safety. Beyond Clinical Trials: Integrated Research Solutions Veeda Lifesciences offers a holistic approach to drug development with a diverse range of research services, including: Preclinical Testing: In vitro and in vivo studies to assess drug safety, efficacy, and toxicity before clinical trials. Regulatory Consulting: Expert navigation of global regulatory landscapes, including US FDA, EMA, MHRA, DCGI, and other health authorities. Medical Writing & Scientific Documentation: Preparation of clinical study reports, investigator brochures, regulatory dossiers, and scientific publications to support regulatory approvals. A Trusted Partner for Advancing Life-Changing Therapies Veeda Lifesciences is committed to upholding the highest standards of scientific integrity, patient-centric research, and global regulatory excellence. Our collaborative approach, coupled with a strong emphasis on quality, innovation, and operational efficiency, makes us the preferred partner for companies seeking to bring transformative therapies to market. For more information, visit: Veeda Lifesciences
Valerian Chem Private Ltd
VProteomics, Valerian Chem Pvt. Ltd. to Showcase Advanced Mass Spectrometry Solutions at BIO International Convention 2025 We are excited to announce that VProteomics, Valerian Chem Pvt. Ltd. will be participating in the Innovative India Pavilion at the BIO International Convention 2025, taking place from June 16–19, 2025, at the Boston Convention & Exhibition Center, USA. As a leading provider of high-end mass spectrometry services, VProteomics specializes in proteomics, metabolomics, and clinical diagnostics, catering to academic institutions, medical researchers, and pharmaceutical companies. Our state-of-the-art laboratory in Noida is equipped with the latest mass spectrometry infrastructure, enabling us to deliver precise and reproducible results. Our Core Competencies: Discovery & Targeted Proteomics: Comprehensive protein analysis to elucidate complex biological processes. Advanced Metabolomics: In-depth metabolite profiling to understand metabolic pathways and disease mechanisms. Clinical Mass Spectrometry: Diagnostic services including biomarker detection, enzyme analysis, and toxicology testing, facilitating early disease diagnosis and personalized medicine. Biologics Characterization: Detailed analysis of biologic therapeutics to ensure efficacy and safety. We invite our esteemed clients, collaborators, and partners to visit our booth at the Innovative India Pavilion to explore potential collaborations and learn more about our contributions to the global biotech landscape. Event Details: Event: BIO International Convention 2025 Dates: June 16–19, 2025 Location: Boston Convention & Exhibition Center, Boston, USA Pavilion: Innovative India Pavilion For more information about our services, please visit our website: www.vproteomics.com We look forward to connecting with you in Boston!
UK Health Security Agency
Come and talk to us at the UK Pavilion (765) about how we can help support your research and development requirements with consultancy and assay development from our world-renowned experts, our wide range of specialist services and diagnostics, our high containment facilities and our ability to provide high throughput laboratory analysis capacity. The UK Health Security Agency (UKHSA) is responsible for planning, preventing and responding to external health threats, and providing intellectual, scientific and operational leadership at national and local level, as well as globally. We are an executive agency, sponsored by the Department of Health and Social Care. The Agency operates a network of laboratories across England including centres of excellence at Colindale (London) and Porton (Wiltshire), providing a range of clinical, reference and public health microbiology services including bacteriology, mycology, virology, immunology, and genomics. Leadership in communicable diseases, field epidemiology and rapid investigations is also supported by real-time surveillance and analysis and emergency preparedness and response activities delivered via regional health protection teams. All our laboratories have active research and development interests, including the evaluation of novel vaccines, antimicrobials, and in vitro diagnostics, and all our clinical laboratories can assist with access to clinical samples, including novel and emerging pathogens. Our key services include conducting 4 million regional laboratory tests, analysing 350,000+ reference samples, performing 190,000 genomic sequences annually, handling 40,000 rare pathogen referrals, and processing 500,000 radiation dosimeters yearly. We also offer advanced diagnostic capabilities, world-leading expertise in vaccine evaluation and phage translation/application, and have one of the strongest behavioural science units in UK Government. We employ 3,000 scientists across 30+ disciplines and we maintain strong partnerships with 500+ universities globally. Our intellectual property portfolio includes 165 patents and 64 trademarks. UKHSA’s unique position as a public health organisation combines scientific expertise, laboratory infrastructure, and research capabilities. Our income generated from commercial services strengthens our core health security work, while our collaborative approach with industry and academia drives public health benefits and economic growth. We provide a comprehensive range of specialist health security services and products, addressing challenges in public health protection and disease surveillance. These consist of a range of clinical, reference and public health microbiology services including bacteriology, mycology, virology, immunology, and genomics. Leadership in communicable diseases, field epidemiology and rapid investigations is also supported by real-time surveillance and analysis and emergency preparedness and response activities delivered via regional health protection teams. Our key services include: Radiation personal dosimetry service (processing ~500,000 dosimeters annually) Regional laboratory testing (4 million tests supporting NHS diagnostics and public health outbreaks) Reference services (350,000+ samples for specific pathogen analysis) Genomic sequencing (90,000 next-generation and 100,000 Sanger sequencing samples annually) Rare and Imported Pathogen Laboratory services (40,000 NHS referrals) UKHSA’s competitive advantages include: One of the strongest behavioural science and insights functions in UK Government Employment of 3,000 scientists across 30+ scientific disciplines Extensive intellectual property portfolio (165 patents and 64 registered trademarks) Strong partnerships with academia (500+ universities globally) Advanced diagnostic capabilities and accelerator programme World-leading expertise in phage translation and application High containment facilities for in vivo and in vitro research (BSL 3 and 4) Our value proposition lies in our unique position as a public health organisation combining scientific expertise, extensive laboratory infrastructure, and research capabilities. The income generated from commercial services strengthens our core health security services, while our collaborative approach with industry and academia drives both public health benefits and economic growth.
TubeWriter
TubeWriter labeling systems is a full-feature instrument for printing directly at high-speed on the sides and caps of plastic, glass, and curved surfaces, including tubes, vials, slides, plates and custom labware. It is designed to address automating laboratory printing for assays, protocols and experiments. TubeWriter labeling withstands the harshest of lab conditions; resistant to chemical solvents and surviving long-term storage at -80C and liquid nitrogen. | TubeWriter is an automated labeling systems that prints directly on the surface of any labware eliminating the need for sticky labels. For laboratories that perform medium to high-throughput applications struggling with manual labeling or paper labels, the TubeWriter prints directly on the sides and caps of tubes, vials, plates and unique labware. TubeWriter prints text, images, and barcodes using UV-curable ink that withstands extreme lab conditions, most harsh chemicals and long-term storage at -80C and liquid nitrogen.